|
|
|
E-mail Inquiries to: info@Erection.me |
See ERECTION.com advertisement in major medical publications Click here to view full ad |
|
|
|
CLICK HERE to try Provigro Natural Supplement Provigro™ may actually help reverse symptoms of ED and improve sexual desire and sex drive...plus performance and stamina too ! |
|
||
|
As Seen On Fox News |
[ Note that poll results shown may not be scientific. ] Start Date: 10/21/06 |
FDA Probes Reports of Blindness With Viagra, Cialis and Levitra ... (click above for Associated Press full story) |
Alprox-TD ® (Alprostadil--Prostaglandin E1) Topical male genital cream for inducing erection ... |
|||
Click Here for Alprox-TD Topical Male Genital Erection Cream Dispensing Demonstration. |
Also Femprox ® (Alprostadil--Prostaglandin E1) Topical female genital cream for increasing women's sexual enhancement. Uprima ® (Apomorphine HCL) Pill for ED dissolves under the tongue. It is currently sold only in Europe and a New Drug Application (NDA) was submitted to U.S. FDA in 10/02. |
||
Click Here for more information on Palatin Technologies, Inc.'s Bremelanotide CLICK HERE To Watch ABC NEWS NIGHTLINE Video Segment About BREMELANOTIDE Read Entire ABC NEWS Story CLICK HERE |
COMING VERY SOON ! BREAKTHROUGH NEW TREATMENT OPTION EXPECTED TO BE APPROVED SOON FOR MEN WHO CANNOT TAKE VIAGRA ®, LEVITRA ® OR CIALIS ® FOR ERECTILE DYSFUNCTION (ED)... DUE TO HIGH BLOOD PRESSURE MEDICATION OR CARDIOVASCULAR DISEASE Bremelanotide (formerly PT-141 ®) Melanocortin-based Nasal spray, the first in a new class of therapies called melanocortin agonists, works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products, including Viagra ®, Levitra ® and Cialis ®, which belong to the class of phosphodiesterase-5 (PDE-5) inhibitors. Bremelanotide is nasally administered and is both non-invasive and fast acting. Importantly, Bremelanotide is not expected to be contraindicated in patients taking nitrates for the treatment of cardiovascular disease. Clinical studies have demonstrated Bremelanotide to be safe and effective and to improve patient experience. Palatin plans to begin Phase 3 trials for erectile dysfunction (ED) in men in the first half of calendar year 2007. A Phase 2B at home study of bremelanotide in female patients with female sexual arousal disorder (FSD) is also anticipated to be completed in the first half of calendar year 2007. SOURCE: PALATIN TECHNOLOGIES, INC. http://palatin.com/pdfs/bremelanotide.pdf
|